ATE475706T1 - Abgeschwächter dengue-serotyp-2-stamm - Google Patents

Abgeschwächter dengue-serotyp-2-stamm

Info

Publication number
ATE475706T1
ATE475706T1 AT06755943T AT06755943T ATE475706T1 AT E475706 T1 ATE475706 T1 AT E475706T1 AT 06755943 T AT06755943 T AT 06755943T AT 06755943 T AT06755943 T AT 06755943T AT E475706 T1 ATE475706 T1 AT E475706T1
Authority
AT
Austria
Prior art keywords
strain
dengue serotype
attenuated dengue
attenuated
serotype
Prior art date
Application number
AT06755943T
Other languages
English (en)
Inventor
Richard Kinney
Claire Huang
Veronique Barban
Jean Lang
Bruno Guy
Original Assignee
Sanofi Pasteur
Ct S For Disease Control And P
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Pasteur, Ct S For Disease Control And P filed Critical Sanofi Pasteur
Application granted granted Critical
Publication of ATE475706T1 publication Critical patent/ATE475706T1/de

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • C12N7/08Inactivation or attenuation by serial passage of virus
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K39/12Viral antigens
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N7/00Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
    • C12N7/04Inactivation or attenuation; Producing viral sub-units
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00Medicinal preparations containing antigens or antibodies
    • A61K2039/51Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/525Virus
    • A61K2039/5254Virus avirulent or attenuated
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24122New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24134Use of virus or viral component as vaccine, e.g. live-attenuated or inactivated virus, VLP, viral protein
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011Details
    • C12N2770/24011Flaviviridae
    • C12N2770/24111Flavivirus, e.g. yellow fever virus, dengue, JEV
    • C12N2770/24161Methods of inactivation or attenuation
    • C12N2770/24164Methods of inactivation or attenuation by serial passage
    • YGENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02ATECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Virology (AREA)
  • Genetics & Genomics (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Microbiology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Molecular Biology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
AT06755943T 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm ATE475706T1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US69127405P 2005-06-17 2005-06-17
PCT/IB2006/001513 WO2006134443A1 (en) 2005-06-17 2006-06-07 Dengue serotype 2 attenuated strain

Publications (1)

Publication Number Publication Date
ATE475706T1 true ATE475706T1 (de) 2010-08-15

Family

ID=37103341

Family Applications (1)

Application Number Title Priority Date Filing Date
AT06755943T ATE475706T1 (de) 2005-06-17 2006-06-07 Abgeschwächter dengue-serotyp-2-stamm

Country Status (18)

Country Link
US (4) US7641908B2 (de)
EP (1) EP1891210B1 (de)
JP (1) JP5075120B2 (de)
KR (2) KR101582163B1 (de)
CN (1) CN101238209B (de)
AR (1) AR053914A1 (de)
AT (1) ATE475706T1 (de)
AU (1) AU2006257621B2 (de)
BR (1) BRPI0613287A2 (de)
CA (1) CA2611954C (de)
DE (1) DE602006015807D1 (de)
IL (1) IL188068A0 (de)
MX (1) MX2007015872A (de)
MY (2) MY144542A (de)
NO (1) NO20076360L (de)
TW (1) TWI375722B (de)
WO (1) WO2006134443A1 (de)
ZA (1) ZA200710752B (de)

Families Citing this family (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain
CU23586A1 (es) * 2005-11-22 2010-10-30 Ct Ingenieria Genetica Biotech Métodos y proteínas para el tratamiento profiláctico y/o terapéutico de los cuatro serotipos del virus de dengue y otros flavivirus
FR2903605A1 (fr) * 2006-07-12 2008-01-18 Sanofi Pasteur Sa Methode d'immunisation contre les quatres serotypes de la dengue
FR2909286B1 (fr) * 2006-12-01 2012-06-08 Sanofi Pasteur Methode d'immunisation contre les 4 serotypes de la dengue
CN101139638B (zh) * 2007-05-08 2010-05-26 深圳太太基因工程有限公司 一种用于检测登革病毒ⅲ型核苷酸片段的引物和探针序列
CN101959527B (zh) 2008-03-05 2016-04-20 赛诺菲巴斯德有限公司 一种使含佐剂的疫苗组合物稳定的方法
EP2143440A1 (de) 2008-07-09 2010-01-13 Sanofi Pasteur Stabilisierungssubstanz und Impfzusammensetzung, die ein oder mehrere abgeschwächte lebende Flaviviridae enthält
US8968996B2 (en) 2009-06-01 2015-03-03 Takeda Vaccines, Inc. Compositions and methods for rapid immunization against dengue virus
AU2010256845B2 (en) * 2009-06-01 2016-09-22 Takeda Vaccines, Inc. Compositions and methods for administration of vaccines against dengue virus
EP2473624B1 (de) 2009-08-31 2019-05-01 Gen-Probe Incorporated Test für dengue-virus
CN102755642B (zh) * 2012-07-13 2014-01-08 中国食品药品检定研究院 一种炭疽疫苗的制备方法
AU2013295016A1 (en) * 2012-07-24 2015-01-29 Sanofi Pasteur Vaccine compositions for prevention against dengue virus infection
SG10201912291YA (en) 2012-07-24 2020-02-27 Sanofi Pasteur Vaccine compositions
BR112015012515B1 (pt) 2012-11-30 2023-04-11 Sanofi Pasteur Uso de antígenos, construções de ácido nucleico ou vetores virais capazes de expressar uma partícula do tipo vírus (vlp) da dengue e de uma vacina contra sarampo, uma vacina contra caxumba e uma vacina contra rubéola
US9878031B2 (en) 2012-12-14 2018-01-30 Takeda Vaccines, Inc. Compositions, methods of administration and uses for trivalent dengue virus formulations
EP2968516B1 (de) 2013-03-15 2022-01-12 Takeda Vaccines, Inc. Zusammensetzungen und verfahren für chimäre dengue-viruskonstrukte in impfstoffen
JP2016523251A (ja) 2013-06-21 2016-08-08 メルク・シャープ・アンド・ドーム・コーポレーションMerck Sharp & Dohme Corp. デングウイルスワクチン組成物およびその使用方法
CN103382509A (zh) * 2013-07-17 2013-11-06 浙江国际旅行卫生保健中心 逆转录-环介导等温扩增检测登革2型病毒的试剂及检测方法
TWI852899B (zh) 2014-09-02 2024-08-21 法商賽諾菲巴斯德公司 疫苗組合物
ES2981476T3 (es) 2014-12-22 2024-10-09 Merck Sharp & Dohme Llc Composiciones de vacunas contra el virus del dengue y métodos de uso de las mismas
EP3316905A1 (de) 2015-07-03 2018-05-09 Sanofi Pasteur Gleichzeitige impfung gegen dengue und gelbfieber
KR102373570B1 (ko) * 2015-11-27 2022-03-10 케이엠 바이올로직스 가부시키가이샤 뎅기 바이러스 약독주를 뱅크화한 생바이러스, 및 그것들을 항원으로 하는 뎅기 백신
CN105999260B (zh) * 2016-05-13 2019-12-10 四川大学 氢氧化铝凝胶-氯化钠复合免疫佐剂及其制备方法和用途
WO2019069130A1 (en) 2017-10-05 2019-04-11 Sanofi Pasteur COMPOSITIONS FOR RECALL VACCINATION AGAINST DENGUE
EP3846849A1 (de) 2018-09-05 2021-07-14 Takeda Vaccines, Inc. Dengue-impfstoff-einheitsdosis und verabreichung davon
US11464815B2 (en) 2018-09-05 2022-10-11 Takeda Vaccines, Inc. Dengue vaccine unit dose and administration thereof
US11426461B2 (en) 2018-09-05 2022-08-30 Takeda Vaccines, Inc. Methods for preventing dengue and hepatitis A

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996040933A1 (en) 1995-06-07 1996-12-19 The Government Of The United States Of America, Represented By The Secretary Department Of Health And Human Services Infectious dengue 2 virus pdk-53 as quadravalent vaccine
EP1165127B1 (de) * 1999-03-26 2008-12-31 Walter Reed Army Institute of Research Multivalenter dengue-virus impfstoff
ATE412738T1 (de) * 2000-05-30 2008-11-15 Univ Mahidol Attenuierte stammen von denguevirus und ihre verwendungen in impfstoffzusammensetzungen
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
CA2966716C (en) * 2001-05-22 2019-11-26 The Government Of The United States Of America, As Represented By The Cretary, Department Of Health And Human Services Development of mutations useful for attenuating dengue viruses and chimeric dengue viruses
ATE481982T1 (de) * 2002-05-03 2010-10-15 Us Gov Health & Human Serv Dengue-vakzine mit einer gemeinsamen 30 nukleotid-deletion im 3'-utr der dengue-typen 1 und 2.
CA2611954C (en) * 2005-06-17 2014-01-28 Sanofi Pasteur Dengue serotype 2 attenuated strain

Also Published As

Publication number Publication date
US20150031857A1 (en) 2015-01-29
TWI375722B (en) 2012-11-01
KR101582163B1 (ko) 2016-01-05
KR20140019034A (ko) 2014-02-13
CN101238209B (zh) 2013-02-13
EP1891210B1 (de) 2010-07-28
US8795688B2 (en) 2014-08-05
CA2611954C (en) 2014-01-28
JP5075120B2 (ja) 2012-11-14
US20100174057A1 (en) 2010-07-08
MX2007015872A (es) 2008-04-21
AU2006257621A1 (en) 2006-12-21
MY144542A (en) 2011-09-30
CA2611954A1 (en) 2006-12-21
US8067566B2 (en) 2011-11-29
KR20080018271A (ko) 2008-02-27
ZA200710752B (en) 2008-12-31
BRPI0613287A2 (pt) 2010-12-28
AU2006257621B2 (en) 2011-08-11
US7641908B2 (en) 2010-01-05
TW200738881A (en) 2007-10-16
WO2006134443A1 (en) 2006-12-21
JP2008546383A (ja) 2008-12-25
DE602006015807D1 (de) 2010-09-09
AR053914A1 (es) 2007-05-23
NO20076360L (no) 2008-03-11
EP1891210A1 (de) 2008-02-27
US20120083585A1 (en) 2012-04-05
MY161457A (en) 2017-04-14
US20070026016A1 (en) 2007-02-01
IL188068A0 (en) 2008-03-20
CN101238209A (zh) 2008-08-06

Similar Documents

Publication Publication Date Title
ATE475706T1 (de) Abgeschwächter dengue-serotyp-2-stamm
IL188041A0 (en) Dengue serotype 1 attenuated strain
ATE469145T1 (de) 4-ä5-methoxy-6-(2-methyl-6-ä1,2,4ütriazol-1-yl-
DE602007009284D1 (de) 3-aza-bicycloä3.1.0ühexanderivate
BRPI0816970A2 (pt) 1,3-dissubstituídas-4-fenil-1h-piridin-2-onas
DK2205562T3 (da) 1,1,1-trifluor-2-hydroxy-3-phenylpropanderivater
DE602007001681D1 (de) 1,3-dioxan-carboxylsäuren
ATE535505T1 (de) Landwirtschaftliche zusammensetzung
DE502006000770D1 (de) Konservierungsmittel
ATE537171T1 (de) Aryl-isoxazol-4-yl-imidazoä1,5-aüpyridin-deriva e
DK1741339T3 (da) Pesticid sammensætning
EP1976974A4 (de) Pneumococcus-serotypen
DK1865813T3 (da) Fastgørelsesbøjle
FI20055434L (fi) Refraktometri
FI20055407A0 (fi) Kalanteri
DE502006003938D1 (de) Roststab
ATE412728T1 (de) Bleichmittel
EP1940415A4 (de) 19,23,24,25,26,27-hexanor-1alpha-hydroxyvitamin d3
DE502005007729D1 (de) Kalander
UA13036S (uk) Барна стійка
ITMI20050295U1 (it) Tovagliette sottopiatto migliorate
DE502006001048D1 (de) Kombileiste
ITFR20050004U1 (it) Traliccio "conte" muniti di due piattinecon tondino distanziatore
ITDP20060026A1 (it) Multisnodo 1
ITDP20060016A1 (it) Multisnodo 2

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties